INLURIYO 200 mg, film-coated tablets 56 tablets
Active ingredients: IMLUNESTRANT, TOSILATE D'IMLUNESTRANT
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet56 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- INLURIYO 200 mg, comprimés pelliculés
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) polychlortrifluoroéthylène PVC-Aluminium de 56 comprimé(s)
- Marketing authorisation holder
- ELI LILLY NEDERLAND BV (PAY-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 22 Jun 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62276016CIP73033913CIP133400930339138Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOSILATE D'IMLUNESTRANTcomprimé | — | SA |
| IMLUNESTRANTcomprimé | 200 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.